levonorgestrel + etonogestrel

"l-University of Campinas, Brazil-endometriosis" refers to a Phase 4 randomized clinical trial (NCT01435109) conducted by the University of Campinas, Brazil, comparing the efficacy of two long-acting reversible contraceptives (LARCs) for the management of endometriosis-associated symptoms. The study evaluates the **levonorgestrel-releasing intrauterine system (LNG-IUS)**, commercially known as **Mirena**, against the **etonogestrel-releasing subdermal implant**, commercially known as **Implanon**. Both interventions are hormonal delivery systems that release synthetic progestogens to induce endometrial atrophy and suppress the hypothalamic-pituitary-ovarian axis. The primary objective of the trial is to compare their effectiveness in controlling chronic pelvic pain and dysmenorrhea in women with a confirmed diagnosis of endometriosis.

Brand names

MirenaImplanonNexplanon

Other names

LNG-IUSENG-implantlevonorgestrel-releasing intrauterine systemetonogestrel-releasing subdermal implant